351 related articles for article (PubMed ID: 26354995)
1. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
Zhang W; Deng J; Sunkara M; Morris AJ; Wang C; St Clair D; Vore M
J Pharmacol Exp Ther; 2015 Nov; 355(2):280-7. PubMed ID: 26354995
[TBL] [Abstract][Full Text] [Related]
2. Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice.
Deng J; Coy D; Zhang W; Sunkara M; Morris AJ; Wang C; Chaiswing L; St Clair D; Vore M; Jungsuwadee P
J Pharmacol Exp Ther; 2015 Nov; 355(2):272-9. PubMed ID: 26354996
[TBL] [Abstract][Full Text] [Related]
3. Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts.
Zhang W; St Clair D; Butterfield A; Vore M
Toxicol Sci; 2016 May; 151(1):44-56. PubMed ID: 26822305
[TBL] [Abstract][Full Text] [Related]
4. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
[TBL] [Abstract][Full Text] [Related]
5. Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment.
Potočnik N; Perše M; Cerar A; Injac R; Finderle Ž
PLoS One; 2017; 12(7):e0181632. PubMed ID: 28727839
[TBL] [Abstract][Full Text] [Related]
6. Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling.
Zhang J; Wang M; Ding W; Zhao M; Ye J; Xu Y; Wang Z; Ye D; Li D; Liu J; Wan J
Biochem Pharmacol; 2020 Oct; 180():114188. PubMed ID: 32750329
[TBL] [Abstract][Full Text] [Related]
7. Mrp1 localization and function in cardiac mitochondria after doxorubicin.
Jungsuwadee P; Nithipongvanitch R; Chen Y; Oberley TD; Butterfield DA; St Clair DK; Vore M
Mol Pharmacol; 2009 May; 75(5):1117-26. PubMed ID: 19233900
[TBL] [Abstract][Full Text] [Related]
8. The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal.
Jungsuwadee P; Zhao T; Stolarczyk EI; Paumi CM; Butterfield DA; St Clair DK; Vore M
Pharmacogenet Genomics; 2012 Apr; 22(4):273-84. PubMed ID: 22293538
[TBL] [Abstract][Full Text] [Related]
9. Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats.
Elberry AA; Abdel-Naim AB; Abdel-Sattar EA; Nagy AA; Mosli HA; Mohamadin AM; Ashour OM
Food Chem Toxicol; 2010 May; 48(5):1178-84. PubMed ID: 20146931
[TBL] [Abstract][Full Text] [Related]
10. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice.
Rocha VC; França LS; de Araújo CF; Ng AM; de Andrade CM; Andrade AC; Santos Ede S; Borges-Silva Mda C; Macambira SG; Noronha-Dutra AA; Pontes-de-Carvalho LC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):659-62. PubMed ID: 26712129
[TBL] [Abstract][Full Text] [Related]
12. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.
McLaughlin D; Zhao Y; O'Neill KM; Edgar KS; Dunne PD; Kearney AM; Grieve DJ; McDermott BJ
Br J Pharmacol; 2017 Nov; 174(21):3677-3695. PubMed ID: 28261787
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
14. Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats.
Haybar H; Goudarzi M; Mehrzadi S; Aminzadeh A; Khodayar MJ; Kalantar M; Fatemi I
Biomed Pharmacother; 2019 Jan; 109():530-535. PubMed ID: 30551518
[TBL] [Abstract][Full Text] [Related]
15. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis.
Abdel-Daim MM; Kilany OE; Khalifa HA; Ahmed AAM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):745-753. PubMed ID: 28785995
[TBL] [Abstract][Full Text] [Related]
16. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
Lee KH; Cho H; Lee S; Woo JS; Cho BH; Kang JH; Jeong YM; Cheng XW; Kim W
Int J Cardiol; 2017 Apr; 232():40-47. PubMed ID: 28159361
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
18. Ameliorative Effect of Cardamom Aqueous Extract on Doxorubicin-Induced Cardiotoxicity in Rats.
Abu Gazia M; El-Magd MA
Cells Tissues Organs; 2018; 206(1-2):62-72. PubMed ID: 30716735
[TBL] [Abstract][Full Text] [Related]
19. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice.
Jungsuwadee P; Cole MP; Sultana R; Joshi G; Tangpong J; Butterfield DA; St Clair DK; Vore M
Mol Cancer Ther; 2006 Nov; 5(11):2851-60. PubMed ID: 17121932
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
